Walter V. Klemp - Jun 20, 2024 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role
CEO and President, Director
Signature
/s/ Jonathan P. Foster by Power of Attorney
Stock symbol
MBRX
Transactions as of
Jun 20, 2024
Transactions value $
-$3,455
Form type
4
Date filed
6/21/2024, 05:00 PM
Previous filing
Jun 18, 2024
Next filing
Jun 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBRX Common Stock Options Exercise +3.75K +8.04% 50.4K Jun 20, 2024 Direct F1
transaction MBRX Common Stock Tax liability -$3.45K -914 -1.81% $3.78 49.5K Jun 20, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBRX Restricted Stock Units Options Exercise $0 -3.75K -2.96% $0.00 123K Jun 20, 2024 Common Stock 3.75K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
F3 On June 20, 2022, the reporting person was granted 15,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.